Sandoz ‘Bucks Trend’ With Completion Of GSK Cephalosporins Deal
CEO Richard Saynor Insists On The Importance Of Investing In Antibiotics
Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics.
You may also be interested in...
Sandoz Invests In Its Unique Antibiotics Offering
In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.
Celltrion Takes Trio Of GGB Awards In Milan
Celltrion has taken home three awards while Sandoz and Dr Reddy’s have walked away with two prizes each, after winners were announced at the Global Generics & Biosimilars Awards 2021, held in Milan, Italy, on 10 November.
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.